Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Advanced SPTP
NCT06914674Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in solid pseudopapillary tumor of the pancreas (SPN), sponsored by Fudan University. Primary endpoint: Progression-free survival at 1 month. Started Mar 2025; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
solid pseudopapillary tumor of the pancreas (SPN)
Beyond the preview
Go deeper on NCT06914674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914674.